Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (76)	3/13/1998 12:44:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

George: >>They license patents related to T-Cells from a company that interest me.<< Thank you for not mentioning the X word again. :-) >>Do you are anyone else think that funds establishing new positions in a stock would bother to try to soften up the market for the stock during the acquisition period, or am I projecting what I would do?<< I believe that it happens all the time...... with the tacit approval and assistance of some influential underwriters. I also feel that, in the past 15 months, there have been two concerted efforts to "soften up" the entire sector. Yeah.... Miljenko and I took a look at CNCT last year. I think that he came to the same conclusion that I did..... rather pass. Amerindo is on topic, sorta, but here's something more (re. Aries/Rosenwald)..... together with a second thread participant, I went to the PGEN annual meeting this week...... one tidbit..... the major academic collaborator for their angio program has moved from Vanderbilt and is now, according to the CSO of PGEN, Chair of Cardiovascular at Stanford. Here's the listing from Stanford's directory..... no mention of Chairman, but close enough..... name: Quertermous, Thomas e-mail: no address on file department: Med/Cardiovascular Medicine position: Professor phone: (650) 723-(edit) fax: (650) 725-(edit) date-updated: Jan 29 1998 12:15AM So..... does anyone who follows this thread have any insight to PGEN, their angiogenesis program, or anything at all to do with the company? Are they on their way to doing a "GNTA", or will they turn and be a (pre-tox) IPIC? Cheers! Rick